Clovis Oncology Welcomes Two New Directors to its Board

  Clovis Oncology Welcomes Two New Directors to its Board

Business Wire

BOULDER, Colo. -- June 13, 2013

Clovis Oncology, Inc. (Nasdaq: CLVS), announced today the addition of two new
members to its Board of Directors, Ginger Graham and Keith Flaherty, M.D.

“We are delighted to add these two gifted individuals to our Board of
Directors as the Company matures into a later-stage developer of oncology
products and ultimately a commercial organization,” said Patrick J. Mahaffy,
president and CEO of Clovis Oncology. “Ginger is a widely respected and
well-known healthcare executive with significant CEO- and Board-level
experience. Keith has highly-relevant experience as a clinician developing
innovative oncology products, in particular targeted therapies with companion
diagnostics. We are really pleased that they have chosen to join us.”

Ginger Graham is the President and CEO of Two Trees Consulting, where she
coaches first-time CEOs of public and private companies. For the last four
years, she has been a senior lecturer at Harvard University and a faculty
member in its Entrepreneurship Unit. Ms. Graham is the former President and
CEO of Amylin Pharmaceuticals, a biopharmaceutical company based in San Diego,
CA focused on diabetes and obesity. Previously, Ms. Graham was Group Chairman,
Office of the President for Guidant Corporation. Ms. Graham serves on the
Boards of Directors for Walgreen Co., Genomic Health, Inc., Surefire Medical,
Elcelyx Therapeutics Inc., Proteus Biomedical and Circle of Life Hospice
Foundation. Ms. Graham has a Bachelor of Science, Agriculture with high honors
from the University of Arkansas and a Master in Business Administration with
distinction from Harvard Business School.

Keith Flaherty, M.D. is an Associate Professor of Medicine at Harvard Medical
School, Associate Physician of Medicine, Hematology/Oncology at Massachusetts
General Hospital, and Director of the Henri and Belinda Termeer Center for
Targeted Therapy, Massachusetts General Hospital Cancer Center. Dr. Flaherty
is also the Deputy Chair for Biomarker Sciences and the Chair of the
Developmental Therapeutics Committee in the Eastern Cooperative Oncology
Group. Dr. Flaherty has served as Principal Investigator for numerous
first-in-human clinical trials with novel, targeted therapies, including the
first in-human trials of the first prospectively developed selective BRAF
inhibitors for metastatic melanoma. Dr. Flaherty has a Bachelor of Science
from Yale University and medical degree from Johns Hopkins University. Dr.
Flaherty trained in internal medicine at Brigham and Women’s Hospital and
completed a medical oncology fellowship at the University of Pennsylvania.

About Clovis Oncology

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring,
developing and commercializing innovative anti-cancer agents in the U.S.,
Europe and additional international markets. Clovis Oncology targets
development programs at specific subsets of cancer populations, and
simultaneously develops diagnostic tools that direct a compound in development
to the population that is most likely to benefit from its use. Clovis Oncology
is headquartered in Boulder, Colorado, and has additional offices in San
Francisco, California and Cambridge, UK.

To the extent that statements contained in this press release are not
descriptions of historical facts regarding Clovis Oncology, they are
forward-looking statements reflecting the current beliefs and expectations of
management made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. Such forward-looking statements
involve substantial risks and uncertainties that could cause our clinical
development programs, future results, performance or achievements to differ
significantly from those expressed or implied by the forward-looking
statements. Such risks and uncertainties include, among others, the
uncertainties inherent in the initiation of future clinical trials,
availability of data from ongoing clinical trials, expectations for regulatory
approvals, and other matters that could affect the availability or commercial
potential of our drug candidates. Clovis Oncology undertakes no obligation to
update or revise any forward-looking statements. For a further description of
the risks and uncertainties that could cause actual results to differ from
those expressed in these forward-looking statements, as well as risks relating
to the business of the company in general, see Clovis Oncology’s Annual Report
on Form 10-K for the year ended December 31, 2012 and its other reports filed
with the Securities and Exchange Commission.


Clovis Oncology, Inc.
Anna Sussman, 303-625-5022
Breanna Burkart, 303-625-5023
Press spacebar to pause and continue. Press esc to stop.